文献速递淋巴瘤

新预后评分纳入绝对淋巴细胞/单核细胞比值、红细胞分布宽度和β2微球蛋白用于R-CHOP治疗的弥漫大B细胞淋巴瘤

New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta-2 microglobulin in patients with diffuse large B-cell lymphoma treated with R-CHOP: Spanish Lymphoma Group Experience (GELTAMO).
PubMed 文献 · Br J Haematol · 2019-11-28

该回顾性研究纳入992例接受R-CHOP治疗的弥漫大B细胞淋巴瘤患者,多因素分析显示年龄、ECOG评分、分期、大包块、B2M、RDW和LMR独立影响无进展生存。基于这些变量构建的新评分较R-IPI能更好识别高危亚组,五年PFS和OS分别为19%和24% vs 45%和59%。

要点

  • 新评分纳入血常规和B2M等易得指标,无需额外检查。
  • 新评分较R-IPI更精确识别高危DLBCL患者。
  • 年龄、ECOG、分期、大包块、B2M、RDW、LMR独立预测PFS。

核心结论

  • 新评分较R-IPI对PFS和OS的高危评估和风险区分更精确。

研究设计与样本

  • 回顾性研究纳入992例接受R-CHOP治疗的弥漫大B细胞淋巴瘤患者。
  • 西班牙淋巴瘤组经验(GELTAMO)。

主要发现

  • 多因素分析中年龄、ECOG-PS、分期、大包块、B2M、RDW和LMR独立与PFS相关。
  • 新评分高危亚组五年PFS和OS为19%和24%,R-IPI为45%和59%。
  • 新评分预测能力优于IPI。

关键数值与推荐

  • 年龄分三组计0、1、2分;ECOG≥3-4计2分;III/IV期、大包块、高B2M、LMR<2·25、RDW>0·96各计1分;最高9分。

临床怎么用

  • 新评分使用血常规和B2M等常规可得指标,可在真实实践中无需额外检查进行风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The International Prognostic Index (IPI) is the most widely used score for non-Hodgkin lymphoma but lacks the ability to identify a high-risk population in diffuse large B-cell lymphoma (DLBCL). Low absolute lymphocyte count and high monocytes have proved to be unfavourable factors. Red-cell distribution width (RDW) has been associated with inflammation and beta-2 microglobulin (B2M) with tumour load. The retrospective study included 992 patients with DLBCL treated with R-CHOP. In the multivariate analysis, age, Eastern Cooperative Oncology Group performance status (ECOG-PS), stage, bulky mass, B2M, RDW, and lymphocyte/monocyte ratio (LMR) were independently related to progression-free survival (PFS). A new prognosis score was generated with these variables including age categorized into three groups (0, 1, 2 points); ECOG ≥ 3-4 with two; stage III/IV, bulky mass, high B2M, LMR < 2·25 and RDW > 0·96 with one each; for a maximum of 9. This score could improve the discrimination of a very high-risk subgroup with five-year PFS and overall survival (OS) of 19% and 24% versus 45% and 59% of R (revised)-IPI respectively. This score also showed greater predictive ability than IPI. A new score is presented including complete blood cell count variables and B2M, which are readily available in real-life practice without additional tests. Compared to R-IPI, it shows a more precise high-risk assessment and risk discrimination for both PFS and OS.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Bento L, Díaz-López A, Barranco G, et al. New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta-2 microglobulin in patients with diffuse large B-cell lymphoma treated with R-CHOP: Spanish Lymphoma Group Experience (GELTAMO). Br J Haematol. 2019. PMID: 31782146. doi:10.1111/bjh.16263

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。